J Cardiovasc Ultrasound.  2010 Sep;18(3):84-85. 10.4250/jcu.2010.18.3.84.

The Effect of High-Dose Valsartan on Left Ventricular Function Following Primary Percutaneous Coronary Intervention

• Park TH

• KMID: 2177304
• DOI: http://doi.org/10.4250/jcu.2010.18.3.84

Abstract

No abstract available.

MeSH Terms

Percutaneous Coronary Intervention
Tetrazoles
Valine
Ventricular Function, Left
Valsartan
Tetrazoles
Valine

Reference

1. Kim SS, Jeon HK, Cho GM, Lee JH, Kim SJ, Park MY, Lee SJ, Shim BJ, Lee DH, Shin WS, Lee JM, Youn HJ. Evaluation of cardiac function by transthoracic echocardiography in subjects with ST-segment elevation myocardial infarction following primary percutaneous coronary intervention according to valsartan dose: the valsartan one center trial. J Cardiovasc Ultrasound. 2010. 18:77–83.

2. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr. American College of Cardiology. American Heart Association. Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004. 44:671–719.

3. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001. 345:1667–1675.

4. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003. 362:759–766.

5. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA. HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009. 374:1840–1848.

6. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003. 349:1893–1906.